Brown Spencer D. reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that Senior VP and General Counsel Spencer D. Brown received a grant of 300,000 employee stock options on January 12, 2026. According to the terms, 25% of the options vest on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on his continued service.
Toutain Stephan reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp reported that its Chief Operating Officer, Stephan Toutain, received a grant of employee stock options on January 12, 2026. The award covers 300,000 options with a right to buy company shares, recorded as a direct ownership position.
The options vest over four years: 25% of the underlying shares vest and become exercisable on January 12, 2027, and the remaining 75% vest in 36 equal monthly installments thereafter, as long as Toutain continues serving the company through each vesting date.
PDS Biotechnology Corp director receives stock option grant
PDS Biotechnology Corp director Gregory Gene Freitag was granted an employee stock option for 54,876 shares of common stock on the reported date. The option has an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.
The stock option will vest in full and become fully exercisable on the first anniversary of the grant date, provided Freitag continues to serve as a director through that date. After this award, he holds 54,876 derivative securities directly in the form of this option grant.
Iliev Ilian reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp director Ilian Iliev received a grant of 54,876 employee stock options on January 12, 2026. These options were awarded at no cost as an equity incentive and will vest in full on the first anniversary of the grant date, provided he continues serving as a director.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp director Ali-Jackson Kamil received a grant of 54,876 employee stock options on January 12, 2026. These options are held as direct ownership and were awarded at a reported price of $0.00 per option. The entire grant will vest and become fully exercisable on the first anniversary of the grant date, provided Kamil continues to serve as a director through that date.
BRAWLEY OTIS W reported acquisition or exercise transactions in this Form 4 filing.
PDS Biotechnology Corp director Otis W. Brawley received a grant of stock options. He was awarded 54,876 Employee Stock Options (Right to Buy), recorded at a grant price of $0.00 per option. The options vest in full on the first anniversary of the grant date, contingent on his continued service as a director.
PDS Biotechnology Corp director Stephen C. Glover received a grant of employee stock options for 54,876 shares on January 12, 2026. The options have an exercise price of $0.00 per share and represent a right to buy the company’s stock.
According to the filing, the entire stock option grant vests and becomes fully exercisable on the first anniversary of the grant date, as long as Glover continues to serve as a director through that date. After this grant, he directly holds options covering 54,876 shares.
PDS Biotechnology Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price required to remain listed on The Nasdaq Capital Market. The closing bid has stayed below $1.00 for 30 straight business days.
The stock continues trading under the symbol PDSB while the company has 180 calendar days, until August 24, 2026, to regain compliance by posting a closing bid of at least $1.00 for at least 10 consecutive business days. If it still fails to comply, Nasdaq may grant a second 180‑day period if other listing standards are met.
If compliance is not restored, the shares could ultimately be delisted, although the company would have the right to appeal any delisting decision. PDS Biotechnology plans to monitor its share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.
PDS Biotechnology Corporation filed a Form 8-K to share its updated February 2026 corporate presentation. The deck focuses on PDS0101, a Versamune-based immunotherapy targeting HPV16-positive head and neck cancers, and PDS01ADC, a tumor-targeted IL-12 immunocytokine.
PDS0101 plus pembrolizumab in first-line HPV16-positive recurrent/metastatic head and neck cancer showed a median overall survival of 39.3 months, compared with a 12–18 month benchmark for pembrolizumab-based regimens, a 77.4% disease control rate, and a 35.8% objective response rate. Treatment-related adverse events were mostly grade 1–2.
The company highlights a pivotal Phase 3 VERSATILE-003 trial with progression-free survival as the primary endpoint for accelerated approval, multiple Phase 2 studies of PDS01ADC across prostate, colorectal, and liver-associated cancers, and more than 12 patent families providing PDS0101 exclusivity through 2042/2043 in key global markets.
PDS Biotechnology Corporation has adopted an amended protocol for its Phase 3 VERSATILE-003 trial of PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer. The amendment designates progression-free survival (PFS) as an interim primary endpoint to support a potential accelerated approval pathway, while median overall survival (mOS) remains the primary endpoint for full approval. After the FDA’s standard 30-day review of the amended protocol to the IND without objection, the company is proceeding under the new design, which it believes may shorten trial duration and make the study more cost efficient.